DWTX news

Dogwood Therapeutics completed a Phase 2b clinical trial for Halneuron, a candidate for chemotherapy-induced neuropathy, reporting top-line results to be announced in November, and closed a $5M private placement with Sealbond Limited for Phase 3 preparation.

Dogwood Therapeutics, Inc. executed a Subscription Agreement for a private placement offering of shares of common stock up to an aggregate amount of $5,000,000.

Dogwood Therapeutics amended its Certificate of Incorporation to increase total authorized shares to 200 million, comprising 195 million common shares and 5 million preferred shares. The amendment provides flexibility for future capital raises and equity transactions.